Discussion of Phase I Data on a Unique anti-VWF Thrombolytic

A summary by Dr. Wolfgang Miesbach: A potential landmark thrombolytic innovation presented at ASH 2025. Thrilled by the exciting Phase 1 data presentation by Marie Scully and co-authors on TGD001, a groundbreaking novel von Willebrand factor (VWF)-targeting thrombolytic:

• First-of-its-kind mechanism: TGD001 is an antibody-enzyme fusion protein—specifically, an anti-VWF antibody fragment fused to a urokinase catalytic domain. This design enables targeted thrombolysis by simultaneously degrading both fibrin and VWF, addressing critical shortcomings of conventional fibrinolytics that often show limited efficacy in VWF-rich or treatment-resistant clots.
• Exceptional safety profile: The Phase 1 trial demonstrated an excellent safety record with no dose-limiting toxicitiesacross single ascending doses (1-2 mg). Importantly, there were no treatment-emergent anti-drug antibodies, and no spontaneous bleeding events occurred—a crucial advantage over broad-spectrum thrombolytic.
• Potent thrombolytic activity: TGD001 demonstrated strong pharmacodynamic evidence of its intended thrombolytic potential, with dose-proportional plasma concentrations and a favorable pharmacokinetic profile (half-life: 2-8 hours)—ideal for a controlled therapeutic window.
• Universal potential: With preclinical evidence supporting efficacy across diverse clot compositions, TGD001 is entering Phase 1/2 trials for immune-mediated thrombotic microangiopathies (iTTP) and acute ischemic stroke, with enrollment now open in Europe. This breadth of therapeutic potential could genuinely transform how we approach thrombotic disorders.
• As we navigate increasingly complex thrombotic conditions—where anatomical location, clot composition, and the role of VWF all influence treatment outcomes—having a universally effective, safe thrombolytic could be transformative for our patients.

Congratulations to Marie Scully and the entire TargED Biopharmaceuticals team on this excellent work.